ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements
Apollo Hospitals Enterprise promoter K Vishweshwar Reddy created a pledge on 200,000 equity shares worth ₹177.78 Crore. This transaction reflects a change in promoter encumbrance status.
Apollo Hospitals Enterprise Limited conducted its 45th Annual General Meeting on August 25, 2026. The proceedings covered routine items and resolutions, including NCD issuance approval.
Apollo started FY27 with 21% revenue growth, driven by a 22% surge in Healthcare Services and improved digital health economics.
Apollo Hospitals reported strong Q1FY27 consolidated revenue growth of 21% YoY to ₹70,435 mio, driven by robust healthcare services and diagnostics performance alongside narrowing digital cash losses.
Apollo Hospitals Enterprise Ltd reported revenue from operations of ₹7,044 Cr (+20.6% YoY) and net profit of ₹610.4 Cr (+38.4% YoY) for Q1 FY27.
Apollo Hospitals Enterprise Limited published newspaper advertisements regarding its 45th Annual General Meeting. The notice includes details for e-voting and meeting access via VC/OAVM.
Apollo Hospitals' 45th AGM notice includes resolutions for director re-appointments, a final dividend, and the issuance of NCDs up to ₹ 750 Crore.
Apollo Hospitals will hold a board meeting on August 12, 2026. The meeting will focus on approving unaudited financial results for the quarter ended June 30, 2026.
Apollo Hospitals held NCLT-convened meetings for creditors and shareholders on June 24, 2026. These meetings considered a composite scheme of arrangement.
Apollo Hospitals announced a Scheme of Arrangement to demerge Apollo Healthtech and restructure governance. The plan seeks shareholder approval to unlock value and improve focus.
Apollo Hospitals convened a meeting for secured creditors to approve its composite scheme of arrangement. The restructuring includes demergers and amalgamations to streamline group operations.
Apollo Hospitals announced the resignation of Mr. Dinesh Madhavan, President – Group Oncology and International. His resignation is effective from the close of business on May 30, 2026.
Apollo Hospitals submitted its Annual Secretarial Compliance Report for FY2026. The auditor reported no non-compliance observations or fines, confirming strong adherence to SEBI regulations.
Apollo Hospitals announced a composite scheme of arrangement involving mergers with subsidiaries like Apollo Healthco and Keimed. The restructuring aims to consolidate operations and enhance shareholder value.
Apollo Hospitals convened a shareholder meeting for June 24, 2026, to approve a composite demerger scheme. The restructuring aims to separate its identified business undertaking.
Apollo Hospitals delivered record FY26 consolidated revenue exceeding ₹25,000 crore, driven by robust performance in its healthcare services and a first-time ₹10,000 crore milestone for Apollo Healthco.
Apollo Hospitals re-appointed Ms. Rama Bijapurkar as Independent Director for a second five-year term. The appointment remains subject to shareholder approval at the next AGM.
Apollo Health and Cloudnine combine maternity and fertility businesses, valuing AHLL's verticals at ₹1,550 Crore. AHLL will hold a 9.9% stake in the combined entity.
Apollo Hospitals provided updated turnover and networth figures for subsidiaries ASHPL and AFCPL following a board meeting. These corrections ensure accurate financial disclosure for investor transparency.
Apollo Hospitals delivered strong FY26 performance with 16% revenue growth and 34% PAT growth. Expansion strategy focuses on adding 2,800+ beds by FY30.
Apollo Hospitals Enterprise Ltd reported revenue from operations of ₹6,606 Cr (+18.1% YoY) and net profit of ₹551.3 Cr (+33.0% YoY) for Q4 FY26.
Apollo Hospitals reported FY26 consolidated revenue of ₹25,229 Crore, a 16% year-on-year increase. The Board also recommended a final dividend of ₹10 per share.
ICRA affirmed Apollo Hospitals' long-term rating at 'ICRA AAA/Stable' for ₹3,000 Crore bank facilities. The affirmation reflects the company's strong credit profile.
Apollo Hospitals received an NCLT order rescheduling stakeholder meetings for its proposed composite scheme of arrangement. New meeting dates for creditors and shareholders are now set.
Apollo Hospitals Enterprise Limited will hold a board meeting on May 20, 2026, to approve audited financial results for the year ended March 2026 and consider a final dividend. The company's trading window remains closed until May 22, 2026, in compliance with insider trading regulations.
Apollo Hospitals Enterprise Limited has scheduled a Board meeting on May 20, 2026, to approve audited financial results for the year ended March 31, 2026. The Board will also consider recommending a final dividend for the financial year. The trading window for designated persons is closed until May 22, 2026.
Apollo Hospitals Enterprise Ltd has scheduled a Board meeting for May 20, 2026. The Board will consider annual audited standalone and consolidated financial results for FY 2025-26 and recommend a final dividend. The trading window for designated persons remains closed until May 22, 2026.
Apollo Hospitals received an NCLT order regarding its proposed composite scheme of arrangement. The tribunal modified meeting dates for equity shareholders and unsecured creditors of various group companies to May 26-27, 2026. This follows the tribunal's refusal to dispense with the meeting of secured creditors.
Apollo Hospitals Enterprise Limited received an NCLT order regarding its composite scheme of arrangement. The tribunal directed convening meetings for secured/unsecured creditors and shareholders in May 2026, while dismissing a prayer to dispense with the secured creditors' meeting.
Apollo Hospitals Enterprise Limited acquired an additional 775,744 equity shares in Apollo Health and Lifestyle Limited (AHLL) for ₹18.69 Crore. This transaction increases the company's total shareholding in AHLL from 99.42% to 100%, making it a wholly-owned subsidiary.